Literature DB >> 889599

Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin.

R R Miller, N A Awan, K S Maxwell, D T Mason.   

Abstract

To elucidate the hemodynamic effects of prazosin, an antihypertensive agent, in congestive heart failure, we studied 10 patients with ischemic cardiomyopathy and severe ventricular dysfunction. After an oral dose of 2 to 7 mg, heart rate was unchanged (P greater than 0.05). One hour after prazosin administration, mean arterial pressure declined from 95 to 78 mm Hg (P less than 0.001); left ventricular filling pressure declined from 30 to 18 mm Hg (P less than 0.001), cardiac index increased from 2.1 to 2.9 liters per minutes per square meter (P less than 0.001), and systemic vascular resistance fell from 2074 to 1156 dynes sec cm-5 (P less than 0.001). In both forearms vascular resistance and venous tone were reduced (86 to 48 mm Hg per ml per 100 g per minute, and 59 to 18 mm Hg per ml, respectively [P less than 0.001]). All responses persisted for a least six hours (P less than 0.01). Prazosin benefits severe congestive heart failure by inducing a sustained fall of both cardiac preload and impedance.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 889599     DOI: 10.1056/NEJM197708112970604

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  31 in total

1.  Afterload reduction in the therapy of heart failure.

Authors:  W H Fennell
Journal:  Tex Heart Inst J       Date:  1982-03

2.  Outcome of scorpion sting envenomation after a protocol guided therapy.

Authors:  Niranjan Biswal; Rani A Bashir; Uday C Murmu; Betsy Mathai; J Balachander; S Srinivasan
Journal:  Indian J Pediatr       Date:  2006-07       Impact factor: 1.967

3.  Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure.

Authors:  A C Tweddel; R G Murray; D Pearson; W Martin; I Hutton
Journal:  Br Heart J       Date:  1982-04

4.  Acute and chronic haemodynamic effects of prazosin in left ventricular failure.

Authors:  L Stein; P R Foster; A W Friedman; J Statza; P L McHenry
Journal:  Br Heart J       Date:  1981-02

5.  Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure.

Authors:  J Mehta; M Iacona; C J Pepine; C R Conti
Journal:  Br Heart J       Date:  1979-12

6.  Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure.

Authors:  K Chatterjee; T A Ports; S Arnold; B Brundage; W Parmley
Journal:  Br Heart J       Date:  1979-12

7.  Prazosin, pharmacokinetics and concentration effect.

Authors:  D N Bateman; D C Hobbs; T M Twomey; E A Stevens; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

8.  Treatment of chronic heart failure with slow release phentolamine.

Authors:  A J Georgopoulos; A Valasidis; D Siourthas
Journal:  Eur J Clin Pharmacol       Date:  1978-07-30       Impact factor: 2.953

Review 9.  The role of vasodilator therapy in the treatment of severe chronic heart failure.

Authors:  M Packer
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 10.  The potential role of MLC phosphatase and MAPK signalling in the pathogenesis of vascular dysfunction in heart failure.

Authors:  Ozgur Ogut; Frank V Brozovich
Journal:  J Cell Mol Med       Date:  2008-12       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.